Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 09, 2024

BUY
$16.88 - $20.33 $5,249 - $6,322
311 Added 222.14%
451 $8,000
Q1 2024

Apr 05, 2024

BUY
$17.63 - $21.74 $229 - $282
13 Added 10.24%
140 $3,000
Q4 2023

Feb 01, 2024

BUY
$14.37 - $19.07 $603 - $800
42 Added 49.41%
127 $2,000
Q3 2023

Oct 11, 2023

BUY
$13.62 - $20.2 $1,157 - $1,717
85 New
85 $1,000
Q1 2022

Apr 21, 2022

SELL
$9.3 - $12.37 $260 - $346
-28 Closed
0 $0
Q4 2021

Jan 31, 2022

SELL
$10.39 - $15.15 $280 - $409
-27 Reduced 49.09%
28 $0
Q1 2021

Sep 15, 2021

BUY
$16.68 - $23.97 $917 - $1,318
55 New
55 $1,000
Q1 2021

Apr 27, 2021

SELL
$16.68 - $23.97 $917 - $1,318
-55 Closed
0 $0
Q4 2020

Sep 15, 2021

BUY
$14.8 - $21.15 $814 - $1,163
55 New
55 $1,000
Q4 2020

Jan 27, 2021

SELL
$14.8 - $21.15 $814 - $1,163
-55 Closed
0 $0
Q3 2020

Sep 15, 2021

BUY
$15.21 - $25.53 $836 - $1,404
55 New
55 $1,000
Q3 2020

Oct 19, 2020

SELL
$15.21 - $25.53 $836 - $1,404
-55 Closed
0 $0
Q2 2020

Sep 15, 2021

BUY
$15.08 - $26.0 $829 - $1,430
55 New
55 $1,000
Q2 2020

Jul 22, 2020

SELL
$15.08 - $26.0 $829 - $1,430
-55 Closed
0 $0
Q1 2020

Sep 15, 2021

BUY
$11.0 - $19.76 $605 - $1,086
55 New
55 $1,000
Q1 2020

Apr 28, 2020

SELL
$11.0 - $19.76 $605 - $1,086
-55 Closed
0 $0
Q4 2019

Sep 14, 2021

BUY
$5.24 - $12.96 $288 - $712
55 New
55 $1,000
Q4 2019

Jan 27, 2020

SELL
$5.24 - $12.96 $288 - $712
-55 Closed
0 $0
Q3 2019

Sep 14, 2021

BUY
$8.15 - $15.88 $448 - $873
55 New
55 $1,000
Q3 2019

Oct 22, 2019

SELL
$8.15 - $15.88 $448 - $873
-55 Closed
0 $0
Q2 2019

Sep 14, 2021

BUY
$13.2 - $20.39 $726 - $1,121
55 New
55 $1,000
Q2 2019

Jul 31, 2019

SELL
$13.2 - $20.39 $726 - $1,121
-55 Closed
0 $0
Q1 2019

Sep 02, 2021

BUY
$15.93 - $26.59 $876 - $1,462
55 New
55 $0

Others Institutions Holding KNSA

About Kiniksa Pharmaceuticals, Ltd.


  • Ticker KNSA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 34,470,400
  • Market Cap $710M
  • Description
  • Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...
More about KNSA
Track This Portfolio

Track Cwm, LLC Portfolio

Follow Cwm, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.